List of life sciences

Estée Lauder Announces New Skin Longevity Initiative, The Next Frontier of Beauty

Retrieved on: 
목요일, 12월 14, 2023
Research, Luxury, Women, Specialty, Health Technology, Consumer, Health, Cosmetics, Retail, Science, Diamond, Life expectancy, Editorial, Norm (mathematics), Aesthetics, Senior, Assistant professor, Reproductive system, Creative, Congress, Human, Movement, Life, Ageing, Style Design College, Ultimate Diamond, Public policy, Weill Cornell Medicine, Beauty, University of California, Berkeley, Skin, University, Global Brands Group, Sirtuin, Murphy, Toxicology, Stanford University, International Chinese Language Program, Biology, Pharmaceutical industry, Management, Psychology, List of life sciences, Dermatology, Medicine, Longevity

Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.

Key Points: 
  • Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.
  • Estée Lauder also announces its support of the Stanford Center on Longevity and its new Program on Aesthetics & Culture, whose work will include research assessing perceptions on longevity and vitality.
  • “The Estée Lauder brand has always been at the forefront of breakthrough skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
  • Building on the brand’s commitment to furthering longevity research, Estée Lauder announces its support of the Stanford Center on Longevity, a cross-disciplinary research center at Stanford University.

Think Bioscience Appoints Wendy Young, Ph.D., to its Scientific Advisory Board

Retrieved on: 
월요일, 10월 30, 2023
Molecule, American Cancer Society, Genomics, Therapy, Scio Diamond Technology Corporation, GV (company), Wake Forest University, Medicinal chemistry, Research, Protein, Journal, Journal of Medicinal Chemistry, Senior, Princeton University, Celera Corporation, Memorial Sloan Kettering Cancer Center, Multiple sclerosis, Genentech, BTK, Chemistry, Patient, Coronavirus Scientific Advisory Board, Pharmaceutical industry, List of life sciences

BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young, Ph.D., to its Scientific Advisory Board. Dr. Young is a seasoned pharmaceutical professional with 30+ years of experience in small molecule research and development

Key Points: 
  • Think Bioscience brings on accomplished biotech executive and drug discovery veteran Wendy Young, Ph.D.
    BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young , Ph.D., to its Scientific Advisory Board.
  • "We are excited to leverage her deep expertise to build Think into an industry-leading research and development organization."
  • Dr. Young currently serves as a director and/or scientific advisor to several biotech companies and is an advisor at Google Ventures.
  • "I'm excited by the elegance of the Think Bioscience platform, which can discover new functional binding sites and access novel chemical matter.

The Estée Lauder Companies Highlights Key Epigenetics & Multi-Ethnic Translational Clinical Research at 33rd IFSCC Congress

Retrieved on: 
목요일, 10월 12, 2023
Congress, Circadian rhythm, Human, Senior, NYSE, Engineering, Doctor of Philosophy, International Federation of Societies of Cosmetic Chemists, Pigment, Biology, ELC, EL, MD, Publishing, Laboratory, PIE, PIH, BrainScope Company, Inc., D, Ageing, Research fellow, Home economics, Environment, Chemistry, Society, Science, MicroRNA, African Americans, Skin, Woman, Research, Physics, Pharmaceutical industry, Nursing, List of life sciences

NEW YORK, Oct. 12, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) shared its latest clinical research findings in an invited keynote address and podium presentation at the 33rd International Federation of Societies of Cosmetic Chemists (IFSCC) Congress, held in Barcelona, Spain, in September. Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal." Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."

Key Points: 
  • Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal."
  • Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."
  • She also explained that, with the right technologies, understanding the positive and negative epigenetic signals provides the ability to reverse skin aging.
  • This body of research is central to the ongoing development of approaches that enable innovations to shift from anti-aging to age reversal.

Medicenna Presents at National Brain Tumor Society's Research Round Table

Retrieved on: 
화요일, 7월 25, 2023
ECA, Glioblastoma, Neuro-Oncology (journal), Registry, Statistics, Survival, National Brain Tumor Society, MDNA, Brain, NBTS, Hospital, The Lancet, Patient, Decompression (diving), Research, FDA, Randomized controlled trial, D.C, Pharmaceutical industry, Medical imaging, List of life sciences

TORONTO and HOUSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, the Company's President and CEO, was invited to participate and present at the Research Roundtable organized by the National Brain Tumor Society (NBTS).

Key Points: 
  • TORONTO and HOUSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, the Company's President and CEO, was invited to participate and present at the Research Roundtable organized by the National Brain Tumor Society (NBTS).
  • The event, titled “Use of External Control Data in Brain Tumor Clinical Trials” took place on July 20, 2023, in Washington, D.C.
    “Medicenna has been recognized for its innovative work in the treatment of rGBM, a uniformly fatal form of brain cancer.
  • Compelling results from the Company's MDNA55 (bizaxofusp) Phase 2b trial were recently published in the journal Neuro-Oncology, and when compared to a well-matched external control, bizaxofusp more than doubled the median survival in end-stage rGBM patients”, said Dr.
  • Further details about incorporation of an ECA in brain tumor clinical trials and more specifically, the bizaxofusp registration trial, can be found at: The Lancet Oncology and Statistics in Biosciences .

The Estée Lauder Companies to Present Novel Scientific Data at World Congress of Dermatology

Retrieved on: 
수요일, 6월 14, 2023
University, Senior, Sirtuin, Skin care, EL, Ageing, Longevity, Woman, Research, Toxicology, Inflammation, Doctor of Philosophy, Science, Chemistry, Congress, WCD, Publishing, Laboratory, ELC, University of California, Berkeley, Engineering, BrainScope Company, Inc., Physics, Biology, Poster, R, Science and technology in Asia, NYSE, Skin, Pharmaceutical industry, Cosmetics, List of life sciences, Dermatology

NEW YORK, June 14, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and its brands will present at the 25th World Congress of Dermatology (WCD) in Singapore from July 3-8, 2023. ELC researchers across 3 brands and ELC Research & Development (R&D) will share novel clinical and preclinical results that demonstrate scientific innovation and leadership across emerging areas of skin health and anti-aging in the form of 5 poster presentations and a satellite symposium during this global event, which takes place every 4 years.

Key Points: 
  • NEW YORK, June 14, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and its brands will present at the 25th World Congress of Dermatology (WCD) in Singapore from July 3-8, 2023.
  • "The breadth and depth of data to be presented further reflects our robust combined R&D and clinical testing capabilities.
  • These highly integrated areas of focus support our exploration of new ingredients or methodologies to ultimately help shape and advance the skin care landscape."
  • The company has 75 years of formulation authority and is deeply integrated into the scientific community, regularly presenting at leading events and publishing in peer-reviewed journals.

Nominations Open for Frederick County Best Places to Work Awards Event to be held in person July 25, 2023

Retrieved on: 
금요일, 3월 31, 2023
Hospitality, Human resources, Foodservice, City Of, Retail, Health care, The Last Best Place, Business, Transport, Welfare, City, Human resource management, Economic development, Social media, Commerce, Management, List of life sciences, Manufacturing

FREDERICK, Md., March 31, 2023 /PRNewswire-PRWeb/ -- Nominations are open for the 2023 Frederick County Best Places to Work Awards with a focus on workplaces that inspire the industry. The Frederick County Office of Economic Development, Frederick County Workforce Services, City of Frederick Department of Economic Development and the Frederick County Chamber of Commerce will hold the annual Best Places to Work awards celebration in person at the Evangelical Reformed United Church of Christ (ERUCC) Downtown Community Room at 15 West Church Street on July 25, 2023 from 5:00pm-6:30pm.

Key Points: 
  • FREDERICK, Md., March 31, 2023 /PRNewswire-PRWeb/ -- Nominations are open for the 2023 Frederick County Best Places to Work Awards with a focus on workplaces that inspire the industry.
  • The Frederick County Office of Economic Development, Frederick County Workforce Services, City of Frederick Department of Economic Development and the Frederick County Chamber of Commerce will hold the annual Best Places to Work awards celebration in person at the Evangelical Reformed United Church of Christ (ERUCC) Downtown Community Room at 15 West Church Street on July 25, 2023 from 5:00pm-6:30pm.
  • Nominations will be accepted from April 1st through April 30, 2023.
  • To nominate your company for the 2023 Frederick County Best Places to Work Awards, visit: http://ow.ly/9QxX50NtQgt

Cartography Biosciences Appoints Chester Wong as VP, Head of Business Development

Retrieved on: 
목요일, 2월 23, 2023
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Medicine, University, Berkeley, Astellas Pharma, Antigen, Malignancy, Business, Patient, Therapy, Hematology, Business development, Multimedia, Keck Graduate Institute, Onyx Pharmaceuticals, Cell biology, Management, Fine chemical, Amgen, List of life sciences

Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive single-cell antigen atlas for immuno-oncology targets, today announced the appointment of Chester Wong as Vice President, Head of Business Development.

Key Points: 
  • Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive single-cell antigen atlas for immuno-oncology targets, today announced the appointment of Chester Wong as Vice President, Head of Business Development.
  • View the full release here: https://www.businesswire.com/news/home/20230223005443/en/
    “We are thrilled to welcome Chester to the Cartography team,” said Kevin Parker, Ph.D., Co-founder and CEO of Cartography Biosciences.
  • He joins Cartography from Amgen, where as Director of Business Development he led the execution of several key deals across a wide range of areas including opportunities within oncology, hematology, and immunology.
  • Previously he served on the corporate development team at Onyx Pharmaceuticals, an Amgen subsidiary, and held key roles at Astellas Pharma and Deallus Consulting.

SRI International Appoints Kathlynn Brown to Biosciences Division President

Retrieved on: 
화요일, 1월 31, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medicine, Government, Molecular biology, Moses Austin, University of Texas Southwestern Medical Center, Damon Runyon, Biochemistry, Biomedical Research, Drug delivery, Doctor of Philosophy, University, San Francisco, Lung cancer, FOX, Communication, American Chemical Society, SRI International, Management, SRI, List of life sciences

SRI International , an independent nonprofit research institute behind countless cutting-edge technological advances, today announced the promotion of Kathlynn Brown to President of its Biosciences Division.

Key Points: 
  • SRI International , an independent nonprofit research institute behind countless cutting-edge technological advances, today announced the promotion of Kathlynn Brown to President of its Biosciences Division.
  • In her eight-year tenure at SRI International, she has helped the organization double down on its impacts in these fields.
  • “I am thrilled that Kathlynn will become the new president of Biosciences division,” said David Parekh, CEO of SRI.
  • Out of a tremendously talented pool of potential candidates, Kathlynn’s scientific background and her work with both government-funded clients and leading pharmaceutical companies have made her the perfect choice for this important role.”
    “For nearly a decade, I have had the privilege of working alongside creative and dedicated scientists at SRI International as we pave the way in bioscience research,” said Kathlynn Brown, incoming President of SRI International biosciences division.

DSM reports 2022 results

Retrieved on: 
목요일, 2월 16, 2023
Material, Anti-corporate activism, Woman, Euronext Amsterdam, Climate change, DSM, Firmenich, Electricity, Injury, Exchange offer, Foodservice, Enterprise value, Employee resource group, Sale, Engineering, World's oldest architectural practices continuously operating, CDP, Nutrition, Food, HNB, CET, 2012 Six-red World Championship, Science, APM, Beauty, Adjustment, Advent International, Safety, Climate, Growth, Mass meeting, Avient Corporation, LANXESS, Exchange, COVID-19, Initial exchange offering, Mental health, Bookkeeping, Renewable energy, Fine chemical, Pharmaceutical industry, Security (finance), Holding company, Offering circular, Health, List of life sciences

1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.

Key Points: 
  • 1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.
  • DSM became a Health, Nutrition & Bioscience ('HNB') company, organized, as of January 1, 2022, in three business groups: Animal Nutrition & Health; Health, Nutrition & Care; and Food & Beverage.
  • An interim dividend for the year 2022 of €0.93 per ordinary share was recognized as a liability in the second quarter of 2022.
  • Subject to the General Meeting of DSM-Firmenich resolving to pay this dividend, eligible DSM shareholders who tender their DSM ordinary shares for DSM-Firmenich ordinary shares will receive a total dividend of about €2.53 over 2022 (vs €2.50 over 2021).

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
화요일, 1월 17, 2023
Biotechnology, Technology, Other Health, Health, General Health, Other Science, Research, Infectious Diseases, Nanotechnology, Genetics, Science, Infection, Severe acute respiratory syndrome coronavirus 2, Transdermal, UCPH Department of Biology, Editorial board, University of Washington Department of Bioengineering, Hepatitis B, NIH, United States Air Force Scientific Advisory Board, CRISPR, Associate, ERC, University, CRS, Internal medicine, Stanford University, Engineer, Degenerative disease, Chair, Pharmaceutics, RNA, Molecular Pharmaceutics, New York Genome Center, Scientist, Ludwig Maximilian University of Munich, Doctor of Philosophy, SNF, MIT, Nervous system, Physiology, BS, Y combinator, Computational linguistics, SAB, MS, PRDS, Drug resistance, JCR, Drug delivery, MIT Department of Brain and Cognitive Sciences, Cognitive science, Medical device, Pharmaceutical industry, Brain, Biology, Carver, List of life sciences, Neuroscience, New York University

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.